Tonix rises on Medicare payer deal for fibromyalgia drug
Seeking Alpha ·
Tonix Pharmaceuticals ( TNXP ) said it secured a managed Medicare payer agreement for its fibromyalgia treatment TONMYA (cyclobenzaprine HCl sublingual tablets), expanding coverage to about 9 million Medicare beneficiaries and bringing its total pharmacy coverage to approximately 145 million lives, effective Jan. 1, 2027.
AI 시장 분석
Tonix Pharmaceuticals announced a Medicare coverage agreement for its fibromyalgia treatment, TONMYA. Effective January 1, 2027, the agreement adds 9 million Medicare beneficiaries, bringing the total coverage to 145 million. This is expected to signal positive growth for the company's revenue base and market share.
상승 영향
- Biotech — TONMYA's Medicare coverage has expanded by 9 million beneficiaries to a total of 145 million, providing a direct catalyst for stable revenue growth and increased market penetration.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 35% · Bearish (Short) 65%
445 participants
Related News
- Saia set up for market share gains into trucking sector upcycle—BofA Securities
- Meta's Louisiana AI Campus Could Top $250 Billion Investment
- Texas Capital names Mo Jamous as chief digital and information officer
- CACI’s gets DoD contract for drone defense at Southern Border
- Tech stocks live updates: Tech stocks fall as AI trade faces scrutiny, SK Hynix falls
- Goldflare reverse takeover terminated after Quitovac withdraws